Silexion Therapeutics Financial Results
Silexion Therapeutics reported Q3 2026 financial results, highlighting the dosing of the first patient in its Phase 2/3 clinical trial of SIL204 for pancreatic cancer. The company strengthened its balance sheet through a public offering and warrant inducement, ending the quarter with $4.8 million in cash and $3.0 million in shareholders' equity.
- Term
- Q3 2026
“In the third quarter, we began treating patients with SIL204 in our Phase 2/3 trial in pancreatic cancer. After opening our first clinical site at Tel Aviv Sourasky Medical Center in July, we dosed the first patient at the end of September. At the same time, our laboratory work continued to strengthen the case for SIL204, with new data suggesting it may help the immune system recognize cancer cells, and showing that it uses natural carriers in the blood to enter cancer cells. Our focus now is on enrolling the first group of patients and bringing more hospitals in Israel and Germany into the trial.”
Ilan Hadar, Chairman and Chief Executive Officer
“During the third quarter, we completed a public offering and a warrant inducement transaction and continued sales under our at-the-market facility, increasing our cash and cash equivalents to $4.8 million and shareholders’ equity to approximately $3.0 million as of September 30, 2026. This financial progress strengthens our balance sheet and supports the continued advancement of SIL204 as we enroll patients in the Phase 2/3 trial.”
Mirit Horenshtein Hadar, Chief Financial Officer